Bausch Health Companies Inc
TSX:BHC
Gross Margin
Bausch Health Companies Inc
Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.
Gross Margin Across Competitors
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| CA |
|
Bausch Health Companies Inc
TSX:BHC
|
3.1B CAD |
71%
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
730.4B USD |
82%
|
|
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP |
56%
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
364B USD |
68%
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
2T DKK |
84%
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
209B CHF |
74%
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
186.9B CHF |
76%
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
161.1B GBP |
82%
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
201.7B USD |
78%
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
163.5B USD |
68%
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
136.6B USD |
75%
|
Bausch Health Companies Inc
Glance View
Bausch Health Companies Inc. stands as a prominent player in the global healthcare arena, with its roots stretching back over a century. Originally known as Valeant Pharmaceuticals, the firm has undergone significant transformation, focusing on a diverse array of health-related products and innovations. The company operates primarily in three segments: Bausch + Lomb/International, Salix, and Ortho Dermatologics. Each of these divisions articulates its commitment to enhancing patients' lives through high-quality products that address the complex challenges of eye care, gastroenterology, and dermatology, respectively. The Bausch + Lomb sector, named after its foundational company, is recognized globally for its wealth of eye health products, including contact lenses, lens care products, and ophthalmic pharmaceuticals. This sector is integral to Bausch Health's revenue stream, contributing significantly through its diverse portfolio of over-the-counter and prescription offerings. At its core, Bausch Health has honed a business model centered around acquiring and developing specialty pharmaceuticals and health-enhancing technologies. Through strategic acquisitions, partnerships, and internal research, the company curates a vast pipeline of treatments and solutions. Revenue generation for Bausch Health is intrinsically linked to its global market footprint, operating in more than 100 countries. Sales teams across these regions work diligently to ensure that healthcare professionals and consumers alike have access to their products. Meanwhile, the company's commitment to innovation helps it remain responsive in rapidly evolving medical fields. The sales and marketing strategies are finely tuned to address regional disparities, leveraging local insights to maximize market penetration and bolster growth. Ultimately, Bausch Health Companies Inc. thrives by bridging high-quality health solutions with unmet global needs, seeking to leave a lasting impact on the lives it touches.
See Also
Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.
Based on Bausch Health Companies Inc's most recent financial statements, the company has Gross Margin of 70.8%.
You don't have any saved screeners yet